Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Collegium Pharmaceutical (COLL) Shares Outstanding (2016 - 2026)

Collegium Pharmaceutical has reported Shares Outstanding over the past 11 years, most recently at $40.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 29.57% year-over-year to $40.7 million; the TTM value through Dec 2025 reached $40.7 million, up 29.57%, while the annual FY2025 figure was $40.7 million, 29.57% up from the prior year.
  • Shares Outstanding for Q4 2025 was $31.7 million at Collegium Pharmaceutical, roughly flat from $31.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $40.4 million in Q2 2025 and troughed at $31.6 million in Q3 2025.
  • A 5-year average of $37.1 million and a median of $37.5 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: decreased 17.68% in 2024 and later grew 29.57% in 2025.
  • Year by year, Shares Outstanding stood at $35.8 million in 2021, then rose by 3.57% to $37.1 million in 2022, then increased by 2.99% to $38.2 million in 2023, then decreased by 17.68% to $31.4 million in 2024, then grew by 29.57% to $40.7 million in 2025.
  • Business Quant data shows Shares Outstanding for COLL at $40.7 million in Q4 2025, $40.6 million in Q3 2025, and $40.4 million in Q2 2025.